For most people, these drugs appear to be relatively safe
Overall, while preclinical findings provide important mechanistic insights, clinical implementation must be guided by realistic exposure levels, safety margins, and well-designed human trials
Its still widely used today
Appetite, Hunger & Food Intake: A 2017 study completed By Professor John Blundell at the University of Leeds in collaboration with Novo Nordisk showed that 12 weeks of a once-weekly dose of Semaglutide led to a ~300kcal lower energy intake following an ad libitum (i.e., an unrestricted breakfast) [10]
A Global, Regional, and National Burden and Quality of Care Index for Schizophrenia: Global Burden of Disease Systematic Analysis 19902019
The same module found a 20% increase in metoprolol Cmax (unchanged AUC), also deemed not clinically significant [1]